Celgene’s Pomalidomide Faces Review, With Confirmatory Trial Waiting In Wings
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Oncologic Drugs Advisory Committee is set to consider next-generation immunomodulator pomalidomide based on Phase II data. But the company is planning to launch a Phase III confirmatory trial by the end of 2012, which may help smooth the review.